Stellar Biotechnologies, California-based world leader in the
sustainable manufacture of the important KLH immune-stimulating molecule for a
variety of immunotherapy and diagnostic applications, today announced financial
results for Q1 2015, the quarter ended December 31, 2014, showing a healthy
increase in revenue, including both product sales and service contracts.
Stellar produces the immune-stimulating protein Keyhole Limpet
Hemocyanin (KLH) used, among other things, for immunotherapies that target cancer,
immune disorders, Alzheimer’s and inflammatory diseases. The company uses
proprietary methods, facilities, and technologies.
First Quarter Ended December 31, 2014 Results:
• Revenues for the
period were $212,661, compared to revenue for the three months ended December
31, 2013 of $58,825. Q1 2015 revenue included product sales of $152,661,
compared to $16,085 for the three months ended December 31, 2013. Q1 2015
contract services revenue was $60,000, compared to $15,000 for the prior year.
• Quarterly net loss for
Stellar dropped dramatically from $5,577,190 for the period ending December 31,
2013 to $1,343,477 for Q1 2015.
• R&D expenses went
down from $548,225 for the period ending December 31, 2013 to $418,821 for Q1
2015.
• Other operating expenses
went down from $1,206,207 for the period ending December 31, 2013 to $1,119,254
for Q1 2015.
In 2014, Stellar changed its fiscal year end from August 31 to
September 31 to synchronize it with calendar quarters. To view the company’s
filings under Form 20-F, Form 10-K, 10-Q and 8-K, visit the U.S. SEC website
(www.sec.gov). To view the company’s filings with the Canadian Securities
Administrators (“CSA”), including the Management Discussion and Analysis and
related consolidated financial statements, visit the CSA’s SEDAR website
(www.sedar.com).
For more information on Stellar Biotechnologies, visit
www.StellarBiotechnologies.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
